ArticleJournal of inflammation research2026
Suxiao Jiuxin Pill Promotes Post-Myocardial Infarction Cardiac Repair by Enhancing Regulatory T Cell Function via the ST2L Signaling Pathway.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical evidence suggests that extended treatment with Suxiao Jiuxin Pill (SJP) significantly reduces the recurrence rates of myocardial infarction (MI), primarily through its modulation of cardiac immune-fibrotic responses. Nonetheless, the precise molecular mechanisms underlying this effect remain to be fully elucidated. Methods: Male C57BL/6J mice were randomly assigned to six groups: sham-operated control, MI + saline (vehicle control), MI + SJP (39, 78, and 156 mg/kg), and MI + dapagliflozin (1.5 mg/kg, positive control). Cardiac function and infarct size were assessed using echocardiography and Masson's trichrome staining. Serum levels of lactate dehydrogenase (LDH), creatine kinase (CK), and creatine kinase-MB (CK-MB) were measured with a Hitachi 7020 automatic biochemical analyzer, while cardiac troponin T (cTnT) levels were quantified via enzyme-linked immunosorbent assay (ELISA). Gene expression analysis was conducted using reverse transcription polymerase chain reaction (RT-PCR). Immune cell populations within the ischemic heart were analyzed through flow cytometry. Naïve CD4 Results: The administration of SJP treatment resulted in a significant reduction in infarct size and enhancement of cardiac function in mice with MI. Additionally, SJP modulated the immune profile of the infarcted myocardium by reducing neutrophil infiltration and increasing the presence of CD4 Conclusion: This study elucidates the cardioprotective effects of SJP, which are mediated through the expansion of the Treg population and enhancement of their immunosuppressive function via activation of the ST2L/Foxp3 signaling pathway, with senkyunolide I and levistolide A identified as primary drivers behind the enhanced Treg function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.